| Participant Role | Details | Start Time | Minutes | Action |
|---|---|---|---|---|
| Application | ORAL HIF-2α INHIBITOR MK-6482 FOR VON HIPPEL-LINDAU (VHL) DISEASE–ASSOCIATED CLEAR CELL RENAL CELL CARCINOMA: EVALUATION OF RCC AND NON-RCC DISEASE | 03:30 PM | 10 | View |
| Application | PREVALENCE OF GERMLINE MUTATIONS IN CANCER SUSCEPTIBILITY GENES IN PATIENTS WITH EARLY ONSET RENAL CELL CARCINOMA | 03:40 PM | 10 | View |
| Application | The Association between the Affordable Care Act on Insurance Status, Cancer Stage, and Overall Survival in Patients with Renal Cancer | 03:50 PM | 10 | View |
| Total: | 30 Minute(s) |
Best of Kidney Cancer
Description
Day: 12/4/2020
Room: Zoom
Time: 3:30 PM - 4:00 PM